SCHEMBL22286089

SCHEMBL22286089

Cc1nn(C)c2[nH]c(-c3ccc(Cl)cc3F)c(O)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 7/20 0.41
MAPK9 P45984 5/20 0.41
MAPK10 P53779 3/20 0.37
PARP1 P09874 3/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PIM1 P11309 2/20 0.34
MAP4K2 Q12851 2/20 0.34
MAP4K4 O95819 1/20 0.34
CSF1R P07333 1/20 0.34
CLK2 P49760 1/20 0.34
MINK1 Q8N4C8 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
MAP4K5 Q9Y4K4 1/20 0.34
HSD11B1 P28845 1/20 0.34
CDK2 P24941 2/20 0.34
CDK9 P50750 2/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
MAP2K1 Q02750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22286110 0.89 PARP1 (0.38) PARP1MEN1KMT2AMAPK13MAPK12
SCHEMBL22286058 0.89 MAPK8 (0.42) MAPK8MAPK9MAPK10PARP1MEN1
SCHEMBL20551344 0.86 MAPK8 (0.42) MAPK8MAPK9MAPK10PARP1MEN1
SCHEMBL22286044 0.86 MAPK8 (0.45) MAPK8MAPK9MAPK10MEN1KMT2A
SCHEMBL20552339 0.85 KDM4E (0.40) PARP1PDGFRB
SCHEMBL20551615 0.85 HSD11B1 (0.37) PARP1HSD11B1NR3C1
SCHEMBL22286159 0.84 HSD11B1 (0.38) MAPK8MAPK9PARP1HSD11B1NR3C1
SCHEMBL20550766 0.81 PARP1 (0.39) MAPK8MAPK9PARP1
SCHEMBL22286022 0.79 LMNA (0.47) PARP1MEN1KMT2AHSD11B1NR3C1
SCHEMBL22286076 0.78 PARP1 (0.40) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US claimed
CN-110914263-A Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors 格兰马克药品股份有限公司 2020-03-24 CN claimed
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US disclosed
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS NOX1, CYBB, NOX4 MAPK8 987/4885MAPK9 1388/4885MAPK10 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.